Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)

Trial Profile

A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms AETHERA
  • Sponsors Seagen; Seattle Genetics; Takeda
  • Most Recent Events

    • 13 Dec 2022 Results assessing the effect of the cumulative maintenance brentuximab vedotin dose on 2-year progression free survival in patients with high-risk relapsed/refractory classical Hodgkin lymphoma, presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 03 Dec 2021 Data was used from this trial and an observational study using a French National Hospital database to assess public health impact by combining clinical trial and real-world data RWD presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 04 Jul 2020 This trial is completed in Hungary (Global End Date: 07 May 2020), according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top